Literature DB >> 12467068

Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study.

Gherardo Mazziotti1, Francesca Sorvillo, Filomena Morisco, Antonella Carbone, Mario Rotondi, Gianfranca Stornaiuolo, Davide F Precone, Michele Cioffi, Giovanni B Gaeta, Nicola Caporaso, Carlo Carella.   

Abstract

BACKGROUND: Although experimental studies have demonstrated an important role of insulin-like growth factor I (IGF-I) in hepatocarcinogenesis, the clinical data about IGF-I in patients with hepatocellular carcinoma (HCC) are scarce and controversial. To the authors' knowledge, this is the first prospective study investigating the longitudinal correlation between modifications in serum IGF-I levels and the development of HCC in a cohort of patients with hepatitis C virus (HCV)-related cirrhosis.
METHODS: One hundred fourteen consecutive patients with HCV-related Child Grade A cirrhosis were followed prospectively at the Second University of Naples for 56.4 +/- 12.0 months with ultrasound examinations of the liver and serum alpha-fetoprotein determination every 6 months. At each clinical evaluation, the severity of disease was graded according to the established Child-Pugh scoring system. Serum IGF-I levels were measured prospectively at the study entry and at least every 12 months throughout follow-up.
RESULTS: Twenty patients (19.2%) developed HCC during follow-up. Eleven of these patients had persistent Child Grade A cirrhosis for the whole study, whereas the other 9 patients developed HCC after their cirrhosis progressed from Child Grade A to Grade B. In patients who remained free of HCC for the whole study, serum IGF-I concentrations did not modify significantly during follow-up. Conversely, in patients who developed HCC, IGF-I levels decreased significantly during follow-up (from 72.6 +/- 29.9 microg/L to 33.8 +/- 14.5 microg/L; P = 0.001). In these patients, the significant decrease occurred both in patients with persistent Child Grade A cirrhosis and in patients with cirrhosis that progressed from Child Grade A to Grade B. The reduction in IGF-I level preceded the diagnosis of HCC by 9.3 +/- 3.1 months.
CONCLUSIONS: This prospective study demonstrates that, in patients with HCV-related cirrhosis, 1) the development of HCC is accompanied by a significant reduction of serum IGF-I levels independent of the grade of impairment of liver function; and 2) modification of the IGF-I level precedes the morphologic appearance of HCC, permitting a precocious diagnosis of the tumor. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.11002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467068     DOI: 10.1002/cncr.11002

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  41 in total

1.  Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases.

Authors:  Karam A Mahdy; Hanaa H Ahmed; Fathia Mannaa; Azza Abdel-Shaheed
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

Review 2.  Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma.

Authors:  Mahmoud Khattab; Magdy Fouad; Elham Ahmed
Journal:  World J Hepatol       Date:  2015-10-18

3.  Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study.

Authors:  Wei-Wen Su; King-Teh Lee; Yao-Tsung Yeh; Maw-Soan Soon; Chao-Ling Wang; Ming-Lung Yu; Shen-Nien Wang
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 4.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

5.  Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study.

Authors:  Yasushi Adachi; Masanori Nojima; Mitsuru Mori; Yasutaka Matsunaga; Noriyuki Akutsu; Shigeru Sasaki; Takao Endo; Youichi Kurozawa; Kenji Wakai; Akiko Tamakoshi
Journal:  Tumour Biol       Date:  2016-09-23

6.  Biochemical/metabolic changes associated with hepatocellular carcinoma development in mice.

Authors:  Nahla E El-Ashmawy; Hoda A El-Bahrawy; Maha M Shamloula; Ola A El-Feky
Journal:  Tumour Biol       Date:  2014-02-13

7.  Influence of gender on serum growth hormone, insulin-like growth factor-I and its binding protein-3 during aging.

Authors:  Chiou-Meei Lin; Yeou-Lih Huang; Zu-Yau Lin
Journal:  Yonsei Med J       Date:  2009-06-24       Impact factor: 2.759

8.  Insulin-like growth factors and liver cancer risk in male smokers.

Authors:  J M Major; R Z Stolzenberg-Solomon; M N Pollak; K Snyder; J Virtamo; D Albanes
Journal:  Br J Cancer       Date:  2010-08-17       Impact factor: 7.640

Review 9.  Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma.

Authors:  Hend Mohamed El Tayebi; Ahmed Ihab Abdelaziz
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

10.  Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection.

Authors:  Eiman Aleem; Ayman Elshayeb; Nihal Elhabachi; Amal Refaat Mansour; Ahmed Gowily; Asmaa Hela
Journal:  Oncol Lett       Date:  2011-12-30       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.